EVO Evotec SE

NASDAQ
$1.65

Evotec SE (EVO) is expected to report earnings on May 6, 2026, before the market open. The consensus earnings estimate is a loss of $0.14 per share.

Earnings Date
3rd Quarter, Sep 2026
May 6
Wednesday · Before Open
Earnings Whisper
-
vs ($0.14)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP -

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Evotec SE

EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries

Sector

Healthcare

Industry

Research Services

Charts powered in part by Lightweight Charts™ by TradingView.